Efficacy and safety of vaccination against hepatitis A and B in patients with chronic liver disease;Eficacia y seguridad de la vacunación para la hepatitis A y la hepatitis B en pacientes con hepatopatía crónica

Gastroenterologia y Hepatologia

Volumn 32, Issue 7, 2009, Pages 483-488

  de Artaza Varasa, Tomás ^a   Sánchez Ruano, Juan José ^a   García Vela, Almudena ^a   Gómez Rodríguez, Rafael ^a   Romero Gutiérrez, Marta ^a   de la Cruz Pérez, Gema ^a   Gómez Moreno, Ana Zaida ^a   Carrobles Jiménez, José María ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Chronic liver disease; Hepatitis A; Hepatitis B; Vaccination

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; SEROCONVERSION;

ADULT; AGED; CHRONIC DISEASE; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 67650979183     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2009.03.009     Document Type: Article

References (35)

1. Almasio P.L., and Amoroso P. HAV infection in chronic liver disease: A rationale for vaccination. Vaccine 21 (2003) 2238-2241
2. Keeffe E.B., Iwarson S., McMahon B.J., Lindsay K.L., Koff R.S., Manns M., et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27 (1998) 881-886
3. Vento S., Garofano T., Renzini C., Cainelli F., Casalli F., Concia E., et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 338 (1998) 286-290
4. Liaw Y.F., Yeh C.T., and Tsai S.L. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 95 (2000) 2978-2980
5. Reiss G., and Keeffe E.B. Hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 19 (2004) 715-727
6. Strader D.B., Wright T., Thomas D.L., Seeff L.B., and American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
7. Centers for Disease Control and Prevention. Recommendations and reports: Hepatitis A and B vaccines. MMWR 52 (2003) 34-36
8. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepatology 36 Suppl 1 (2002) S3-S20
9. Keeffe E.B. Acute hepatitis A and B in patients with chronic liver disease: Prevention through vaccination. Am J Med 118 (2005) 21S-27S
10. Davis J.P. Experience with hepatitis A and B vaccines. Am J Med 118 (2005) 7S-15S
11. Navas E., Bayas J.M., Bruguera M., Vidal J., Galí N., Taberner J.L., et al. Eficiencia de la detección prevacunal de anti-VHA en los programas de vacunación antihepatitis A. Med Clin (Barc) 105 (1995) 168-171
12. Diago M., Luján V., García R., Cors R., Carbonell P., Tuset C., et al. Prevalencia de anti-VHA en pacientes con hepatopatía crónica. Gastroenterol Hepatol 21 (1998) 324-326
13. Duncan M., Hirota W.K., and Tsuchida A. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: A prospective cost analysis. Am J Gastroenterol 97 (2002) 1792-1795
14. Jacobs R.J., Koff R.S., and Meyerhoff A.S. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 97 (2002) 427-434
15. Lau D.T.-Y., and Hewlett A.T. Screening for hepatitis A and B antibodies in patients with chronic liver disease. Am J Med 118 Suppl 10A (2005) 28S-33S
16. Jakiche R., Borrego M.E., Raisch D.W., Gupchup G.V., Pai M.A., and Jakiche A. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses. Am J Med Sci 333 (2007) 26-34
17. Lee S.D., Chan S.Y., Yu M.I., Wang Y.J., Chang F.Y., and Lo K.J. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. J Med Virol 52 (1997) 215-218
18. Tsang S.W., and Sung J.J. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment Pharmacol Ther 13 (1999) 1445-1449
19. Arguedas M.R., Johnson A., Eloubeidi M.A., and Fallon M.B. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 34 (2001) 28-31
20. Dumot J.A., Barnes D.S., Younossi Z., Gordon S.M., Avery R.K., Domen R.E., et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 94 (1999) 1601-1604
21. Wiedmann M., Liebert U.G., Oesen U., Porst H., Wiese M., Schroeder S., et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 31 (2000) 230-234
22. Daryani N.E., Nassiri-Toosi M., Rashidi A., and Khodarahmi I. Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study. World J Gastroenterol 13 (2007) 294-298
23. Lee S.D., Chan C.Y., Yu M.I., Lu R.H., Chang F.Y., and Lo K.J. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 59 (1999) 463-468
24. De María N., Idilman R., Colantoni A., and Van Thiel D.H. Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis. J Viral Hepat 8 (2001) 372-376
25. Idilman R., De María N., Colantoni A., Nadir A., and Van Thiel D.H. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 97 (2002) 435-439
26. Mendenhall C., Roselle G.A., Lybecker L.A., Marshall L.E., Grossman C.J., Myre S.A., et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. Dig Dis Sci 33 (1998) 263-269
27. Domínguez M., Bárcena R., García M., López-Sanromán A., and Nuño J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 6 (2000) 440-442
28. Keeffe E.B. Vaccination against hepatitis A and B in chronic liver disease. Viral Hepat Rev 5 (1999) 77-88
29. Mattos A.A., Gomes E.B., Tovo C.V., Alexandre C.O., and Remiao J.O. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 41 (2004) 180-184
30. Elefsiniotis I.S., Vezali E., Kamposioras K., Pantazis K.D., Tontorova R., Ketikoglou I., et al. Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment. World J Gastroenterol 12 (2006) 4420-4424
31. Poland G.A., and Jacobson R.M. Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 351 (2004) 2832-2838
32. Wörns M.A., Teufel A., Kanzler S., Shrestha A., Victor A., Otto G., et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 103 (2008) 138-146
33. Joines R.W., Blatter M., Abraham B., Xie F., De Clerq N., Baine Y., et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 19 (2001) 4710-4719
34. Koff R.S. Hepatitis A, hepatitis B and combination hepatitis vaccines for immunoprophylaxis: An update. Dig Dis Sci 47 (2002) 1183-1194
35. Bockhold K., Riely C.A., and Jeffreys C. Overcoming obstacles to immunization in patients with chronic liver disease. Am J Med 118 (2005) 40S-45S